|

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

RECRUITINGN/ASponsored by Seoul National University Bundang Hospital
Actively Recruiting
PhaseN/A
SponsorSeoul National University Bundang Hospital
Started2022-03-10
Est. completion2025-06-30
Eligibility
Age19 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05557123

Summary

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention).
* patients who already took or plan to take rivoxban
* patients who able to use smart phone

Exclusion Criteria:

* creatinine clearance \<15ml/min
* moderate or severe mitral stenosis
* mitral valve operation history
* current alcohol abuse or alcohol abus history
* Not eligible for study due to legal or psychiatric problem
* enrolled other clinical study within 4 weeks
* declined to enroll the study

Conditions2

Atrial FibrillationHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.